meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic-recurrent HNSCC (mHNSCC)
mHNSCC - (neo)adjuvant (NA)
mHNSCC - 1st line (L1)
mHNSCC - L1 - all population
2
mHNSCC - L1 - PDL1 positive
4
mHNSCC - 2nd line (L2)
mHNSCC - L2 - all population
4
mHNSCC - L2 - PDL1 negative
2
mHNSCC - L2 - PDL1 positive
1
hepatocell cancer (HCC)
1
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab plus bevacizumab
atezolizumab plus cabozantinib
camrelizumab based treatment
durvalumab based treatment
durvalumab plus bevacizumab
nivolumab based treatment
nivolumab alone
pembrolizumab based treatment
pembrolizumab alone
pembrolizumab plus lenvatinib
sintilimab based treatment
sintilimab
Tislelizumab
Immune checkpoint association
durvalumab plus tremelimumab
nivolumab plus ipilimumab
nivolumab plus ipilimumab plus SoC
VEGF(R) inhibitor
bevacizumab based treatment
bevacizumab
versus all
vs chemotherapy
vs Standard of Care (SoC)
vs immune chekpoint inhibitors
vs anti-PD-(L)1
vs nivolumab based treatment
vs nivolumab alone
vs non active control
vs placebo
vs VEGF(R) inhibitor
vs lenvatinib
vs sorafenib
All patients
Age < 65y (younger)
Age > 65y
BCLC B
BCLC C
ECOG 0
ECOG 1
Gender, female
Gender, male
viral status HBV
viral status HCV
viral status uninfected
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
button
bars
forest
bayes
pooled
summary
circles
DCR
deaths (OS)
deaths (OS) (extension)
DOR
objective responses (ORR)
PFS (extension)
progression or deaths (PFS)
RFS/DFS
AE (any grade)
AE (grade 3-4)
AE (grade 3-5)
AE leading to death (grade 5)
AE leading to treatment discontinuation (any grade)
AE leading to treatment discontinuation (grade 3-4)
SAE (any grade)
STRAE (grade 3-4)
TRAE (any grade)
TRAE (grade 3-4)
TRAE leading to death (grade 5)
TRAE leading to discontinuation (any grade)
Abdominal pain TRAE (grade 3-4)
Adrenal insufficiency TRAE (grade 3-4)
Alopecia TRAE (grade 3-4)
Anaemia TRAE (grade 3-4)
Arthralgia TRAE (grade 3-4)
Asthenia TRAE (grade 3-4)
Colitis TRAE (grade 3-4)
Constipation TRAE (grade 3-4)
Cough TRAE (grade 3-4)
Decreased appetite TRAE (grade 3-4)
Diabetes TRAE (grade 3-4)
Diarrhoea TRAE (grade 3-4)
Dry skin TRAE (grade 3-4)
Dysgeusia TRAE (grade 3-4)
Dyspepsia TRAE (grade 3-4)
Dyspnoea TRAE (grade 3-4)
Eczema TRAE (grade 3-4)
Fatigue TRAE (grade 3-4)
Headache TRAE (grade 3-4)
Hepatitis TRAE (grade 3-4)
Hypertension TRAE (grade 3-4)
Hyperthyroidism TRAE (grade 3-4)
Hypophysitis TRAE (grade 3-4)
Hypothyroidism TRAE (grade 3-4)
Increase AST TRAE (grade 3-4)
Increased ALT TRAE (grade 3-4)
Infusion-related reactions TRAE (grade 3-4)
Leucopenia TRAE (grade 3-4)
Maculopapular rash TRAE (grade 3-4)
Myalgia TRAE (grade 3-4)
Myositis TRAE (grade 3-4)
Nausea TRAE (grade 3-4)
Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4)
Peripheral oedema TRAE (grade 3-4)
Pneumonitis TRAE (grade 3-4)
Proteinuria TRAE (grade 3-4)
Pruritus TRAE (grade 3-4)
Pyrexia TRAE (grade 3-4)
Rash TRAE (grade 3-4)
Severe skin reaction TRAE (grade 3-4)
Stomatitis TRAE (grade 3-4)
Thrombocytopenia TRAE (grade 3-4)
Thyroiditis TRAE (grade 3-4)
Vomiting TRAE (grade 3-4)
Weight decreased TRAE (grade 3-4)
Abdominal pain AE (grade 3-4)
Acute kidney injury AE (grade 3-4)
Alopecia AE (grade 3-4)
Anaemia AE (grade 3-4)
Arthralgia AE (grade 3-4)
Asthenia AE (grade 3-4)
Back pain AE (grade 3-4)
Constipation AE (grade 3-4)
Cough AE (grade 3-4)
Decreased appetite AE (grade 3-4)
Diarrhoea AE (grade 3-4)
Dyspepsia AE (grade 3-4)
Dyspnoea AE (grade 3-4)
Epistaxis AE (grade 3-4)
Fatigue AE (grade 3-4)
Hypertension AE (grade 3-4)
Increase AST AE (grade 3-4)
Increased ALT AE (grade 3-4)
Infusion-related reaction AE (grade 3-4)
Nausea AE (grade 3-4)
Palmar–plantar erythrodysesthesia syndrome AE (grade 3-4)
Peripheral oedema AE (grade 3-4)
Proteinuria AE (grade 3-4)
Pruritus AE (grade 3-4)
Pyrexia AE (grade 3-4)
Rash AE (grade 3-4)
Thrombocytopenia AE (grade 3-4)
Vomiting AE (grade 3-4)
Weight decreased AE (grade 3-4)
DCR
hepatocell cancer (HCC)
hepatocell cancer (HCC)
versus placebo
durvalumab plus bevacizumab vs. placebo
1
pembrolizumab based treatment vs. placebo
1
versus sorafenib
Tislelizumab vs. sorafenib
1
versus Standard of Care (SoC)
sintilimab vs. Standard of Care (SoC)
1
mHCC - (neo)adjuvant (NA)
metastatic/advanced hepatocellular cancer (mHCC)
mHCC - (neo)adjuvant (NA)
versus Standard of Care (SoC)
atezolizumab plus bevacizumab vs. Standard of Care (SoC)
1
sintilimab vs. Standard of Care (SoC)
1
mHCC - 1st line (L1)
metastatic/advanced hepatocellular cancer (mHCC)
mHCC - 1st line (L1)
versus lenvatinib
pembrolizumab plus lenvatinib vs. lenvatinib
1
versus placebo
durvalumab plus bevacizumab vs. placebo
1
versus sorafenib
atezolizumab plus bevacizumab vs. sorafenib
1
atezolizumab plus cabozantinib vs. sorafenib
1
camrelizumab based treatment vs. sorafenib
1
nivolumab alone vs. sorafenib
1
sintilimab vs. sorafenib
1
Tislelizumab vs. sorafenib
1
mHCC - 2nd line (L2)
metastatic/advanced hepatocellular cancer (mHCC)
mHCC - 2nd line (L2)
versus placebo
pembrolizumab alone vs. placebo
1
1.44
pembrolizumab based treatment vs. placebo
1
1.44
×
delta: difference in rate or median (if available)
×
Extraction panel open
An extraction panel is open